Ionis secures FDA approval for zilganersen, a first treatment for Alexander disease

Ionis Pharmaceuticals announced that the U.S. Food and Drug Administration has approved its antisense drug zilganersen for the treatment of Alexander disease, an ultra‑rare neurodegenerative disorder.

The condition, which typically leads to rapid neurological decline in young children, has long lacked effective therapies. Families often receive a grim prognosis, as illustrated by the story of Elise, who was diagnosed after severe seizures and was told she might not survive past early childhood.

The approval marks a significant milestone for Ionis, adding a new pillar to its rare‑disease pipeline and demonstrating the potential of antisense technology in addressing previously untreatable genetic disorders.

Elise’s mother founded a nonprofit to fund research into the disease, and the new therapy offers renewed hope for patients and caregivers seeking disease‑modifying options.